Skip to content
Search

Latest Stories

Calls for urgent action to avert disruption of cannabis-based medicinal products due to Brexit

The Centre for Medicinal Cannabis (CMC) has urged the authorities to take quick steps for a broad and customised range of CBMPs that can be rapidly and cost effectively imported into, or developed and produced within the UK to avert the scarcity of such medicines due to Brexit.

For a short term solution to help families that could potentially face a disruption in the vital supply of cannabis-based medicinal products (CBMPs), their children need, the CMS has adviced the patients to seek alternative legal routes to obtaining CBMPs within the UK.


“Currently, this is only possible through private practises, however, recent reductions in price mean that this is now more affordable than ever. Mechanisms exist to decrease the financial burden on families where necessary,” it said.

Earlier, there were media reports highlighting over 40 patients who have been prescribed certain CBMPs in the UK but can only obtain their prescription through the Transvaal Pharmacy, which is based in the Netherlands. However, European pharmacies are no longer obliged to honour UK prescriptions during the post Brexit transition period.

The CMC has assured all stakeholders that it will continue to work constructively with the Department of Health and Social Care (DH) to provide full transparency on what is currently available.

“Supply issues and discontinuations of medicines have always been a difficult challenge for the medical community to deal with, especially when dealing with vulnerable patients who are stabilised on a particular medicine,” said Dr Andy Yates, pharmacy lead for CMC.

“This situation is exacerbated when you are dealing with a complex medicine such as CBMPs. Working with our members, we have been able to provide the DH with a list of CBMPs that may be suitable for substitution, but as the article points out they do have differences in composition and would therefore require careful medical management if a solution to supplying Transvaal products cannot be found”.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less